| pubmed-article:9275033 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C0030190 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C0600558 | lld:lifeskim |
| pubmed-article:9275033 | lifeskim:mentions | umls-concept:C1546988 | lld:lifeskim |
| pubmed-article:9275033 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:9275033 | pubmed:dateCreated | 1997-9-17 | lld:pubmed |
| pubmed-article:9275033 | pubmed:abstractText | There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary tumour to cytotoxic drug regimens. The goal of the study was to assess prospectively the predictive value of PAI-1 for response to first-line chemotherapy. PAI-1 concentration was measured on hypertonic cytosolic extracts (0.4 M potassium chloride) by ELISA before chemotherapy on a drill biopsy sample of the tumour in 69 T2 and T3 breast cancer patients (median age 46 years). Oestrogen receptor (ER) (51% ER+), progesterone receptor (PR) (58% PR+), S-phase (median 4.0%) and ploidy were also assessed in the majority of cases. The clinical response to treatment was evaluated after four cycles of FAC or FEC regimen (5-fluorouracil, epidoxorubicin or doxorubicin and cyclophosphamide) (one cycle every 4th week). PAI-1 could be assayed in 29 post-chemotherapy surgical samples. The objective response rate (complete response plus partial response) was 59% (41 out of 69). PAI-1 expressed as gram of tissue (range 19-2370 ng g(-1) tissue) was highly correlated (r = 0.98) to PAI-1 expressed as mg protein (range 0.5-68 ng mg(-1) protein). No correlation between PAI-1 level and response could be observed, with any cut-off. The post- and pre-chemotherapy PAI-1 levels were correlated (r = 0.66). Of all biological parameters, only high S-phase (cut-off 5%) was slightly correlated (chi2 = 3.91, P = 0.05) to response. These data suggest that PAI-1 is not a predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy. | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9275033 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9275033 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9275033 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9275033 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:9275033 | pubmed:author | pubmed-author:PouillartPP | lld:pubmed |
| pubmed-article:9275033 | pubmed:author | pubmed-author:MagdelénatHH | lld:pubmed |
| pubmed-article:9275033 | pubmed:author | pubmed-author:BeuzebocPP | lld:pubmed |
| pubmed-article:9275033 | pubmed:author | pubmed-author:PiergaJ YJY | lld:pubmed |
| pubmed-article:9275033 | pubmed:author | pubmed-author:Lainé-BidronC... | lld:pubmed |
| pubmed-article:9275033 | pubmed:author | pubmed-author:De CrémouxPP | lld:pubmed |
| pubmed-article:9275033 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9275033 | pubmed:volume | 76 | lld:pubmed |
| pubmed-article:9275033 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9275033 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9275033 | pubmed:pagination | 537-40 | lld:pubmed |
| pubmed-article:9275033 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:meshHeading | pubmed-meshheading:9275033-... | lld:pubmed |
| pubmed-article:9275033 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9275033 | pubmed:articleTitle | Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer. | lld:pubmed |
| pubmed-article:9275033 | pubmed:affiliation | Physiopathology Laboratory and Medical Oncology Department, Institute Curie, Paris, France. | lld:pubmed |
| pubmed-article:9275033 | pubmed:publicationType | Journal Article | lld:pubmed |
